drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Chimeric IgG1 monoclonal antibody against TNF-α; binds soluble and transmembrane TNF-α to block TNFR1/2 signaling (e.g., NF-κB/MAPK), reduce pro-inflammatory cytokines and adhesion molecules, and induce apoptosis of TNF-expressing activated T cells and macrophages; may mediate ADCC/CDC. Administered subcutaneously after switching from prior IV infliximab.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Infliximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody that binds soluble and transmembrane TNF-α, neutralizing TNF and blocking TNFR1/2 signaling (e.g., NF-κB/MAPK), thereby reducing pro‑inflammatory cytokines and adhesion molecules; can induce apoptosis of TNF-expressing activated immune cells and may mediate ADCC/CDC.
drug_name
CT-P13 (biosimilar infliximab, subcutaneous)
nct_id_drug_ref
NCT06381518